Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979781 · ClinicalTrials.gov registry record · Phase 2
Personalized Antiplatelet Secondary Stroke PRevenTion
A Phase 2 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT03979781 is a Phase 2 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 90 participants.
The verdict
NCT03979781, a Phase 2 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a descriptive study designed to evaluate the safety and feasibility of a precision medicine approach to antiplatelet selection for secondary stroke prevention.
Interventions
- DRUG standard of care
- DRUG tailored antiplatelet selection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03979781
The ClinicalTrials.gov registry entry for NCT03979781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which standard of care is the first listed.
NCT03979781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03979781 about?
NCT03979781 is a clinical study titled "Personalized Antiplatelet Secondary Stroke PRevenTion". This is a descriptive study designed to evaluate the safety and feasibility of a precision medicine approach to antiplatelet selection for secondary stroke prevention.
What is the current status of trial NCT03979781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2018-06-11. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT03979781?
The interventions under investigation include: standard of care (DRUG), tailored antiplatelet selection (DRUG).
Who is sponsoring clinical trial NCT03979781?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.